Compare
Amneal Pharmaceuticals vs Lilly (Eli) (AMRX vs LLY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amneal Pharmaceuticals (AMRX) returned +72.3% and Lilly (Eli) (LLY) +46.2%; so far this year the figures are +59.8% and +26.0%.
Lilly (Eli) is the larger company by market value, about 198.1 times the size of Amneal Pharmaceuticals.
On trailing earnings, AMRX trades at 41.1 times and LLY at 43.9 times.
Revenue grew +9.3% at AMRX and +45.5% at LLY over the last year.
AMRX pays no dividend. LLY yields 0.49%.
Data as of the latest close. Not investment advice.
Relative performance
| AMRX | LLY | |
|---|---|---|
| Price | $20.14 | $1,354.00 |
| 1-day | +3.55% | -0.79% |
| YTD | +59.84% | +25.99% |
| 1 year | +72.28% | +46.25% |
| 3 years | +417.74% | +144.20% |
| Market cap | $6.4B | $1.27T |
| P/E | 41.1 | 43.9 |
| P/S | 2.06 | 14.73 |
| P/B | 194.76 | 31.63 |
| Revenue growth | +9.30% | +45.50% |
| EPS growth | +4800.00% | +50.70% |
| Gross margin % | 39.3 | 83.6 |
| Net margin % | 5.0 | 31.9 |
| ROE % | 476.5 | 68.5 |
| Debt / equity | 77.83 | 1.23 |
| FCF yield % | 2.0 | 2.4 |
| Dividend yield % | — | 0.49 |
| Beta | 0.62 | 0.29 |
| RSI (14) | 50.8 | 61.1 |
| Technical rating |